Company Performance Metrics
- Qinghua Xu: Founder, President & Chief Executive Officer
- Hong Zhang: Vice President & Chief Operating Officer
In a world facing a projected 26 million new cancer cases annually by 2030, the demand for innovative, accessible diagnostic solutions has never been more critical. The global precision diagnostics market is poised for explosive growth, reaching USD 50.3 billion by 2030 with a CAGR of 18.4% from 2024 onward.
Canhelp Genomics is at the forefront
of this transformation—a commercial-stage, China-based leader in AI-powered healthcare, delivering cutting-edge tumor diagnostics that leverage high-throughput genomic profiling and advanced AI algorithms for early cancer detection and personalized treatment.
With over 10 years of clinical-grade solution development and a robust portfolio of 50+ patents, Canhelp Genomics combines proprietary RNA profiling technology with a state-of-the-art AI/ML platform to achieve unmatched accuracy, efficiency, and scalability in oncology diagnostics. Our flagship offerings are redefining standards of care:
1 - Canhelp®-Origin Test The world's only China NMPA- and CE-IVD dual-approved "AI+RNA" pan-cancer diagnostic solution, granting us first-mover advantage in the EU and China markets. A landmark randomized Phase 3 trial, published in The Lancet Oncology, demonstrated a 32% improvement in patient survival, establishing it as a potential global standard-of-care.
2 - Canhelp®-MSI Test A revolutionary deep-learning tool for microsatellite instability (MSI) detection that slashes testing workloads by 90%, accelerates diagnoses, and drives down costs. Designated as a "Breakthrough Device" by China's NMPA—the first AI-driven Class III innovative medical device in digital pathology.
3 - Canhelp®-UCa Test The premier urine-based liquid biopsy for early detection and recurrence monitoring of urothelial carcinoma, marking the first China NMPA- and CE-IVD-approved urine RNA diagnostic test.
4 - Canhelp®-PCa Test (in pipeline) A next-generation urine RNA assay targeting the $800 million prostate cancer diagnostics sector, with preliminary studies showing exceptional sensitivity for high-risk patient identification.
Endorsed by renowned physicians and institutions across Asia and Europe, Canhelp Genomics benefits from unparalleled clinical credibility and global visibility. Our scalable, ISO-13485-certified GMP facilities in Hangzhou and Suzhou, China, support an annual capacity of 100,000 tests, complemented by a dedicated AI research center fueling pipeline expansion.
